Poor Investigations, Documents Lead 2013 Form 483 Observations

Drug GMP Report
A A
Poor investigations into batch failures and lax procedural documentation were the top reasons drugmakers received FDA Form 483s in 2013.

To View This Article:

Login

Subscribe To Drug GMP Report

Buy This Article Now

Add this article to your cart for $40.00